Outcome by randomizations
| Group . | Events/patients, no. . | 5-y EFS ± SE, % . | P . |
|---|---|---|---|
| Investigational window, | |||
| Dexamethasone (mg/m2/d) | |||
| 6 | 14/88 | 85 ± 4 | .73 |
| 18 | 18/89 | 80 ± 5 | |
| 150 | 17/86 | 79 ± 5 | |
| Prednisone (mg/m2/d) | |||
| 40 | 13/85 | 87 ± 4 | |
| Asparaginase preparation | |||
| E coli | 15/92 | 84 ± 4 | .29 |
| PEG | 24/106 | 78 ± 4 | |
| 6-MP dosing | |||
| Standard dose (PO) | 26/163 | 84 ± 3 | .90 |
| High dose (IV) | 26/159 | 85 ± 3 | |
| Doxorubicin infusion rate (HR only) | |||
| Bolus | 20/102 | 80 ± 4 | .23 |
| Continuous infusion for 48 h | 14/102 | 86 ± 4 | |
| CNS radiation fractionation | |||
| HR only | |||
| Conventional | 12/96 | 87 ± 3 | .05 |
| Hyperfractionation | 23/97 | 76 ± 4 | |
| SR only | |||
| Conventional | 5/31 | 90 ± 5 | .84 |
| Hyperfractionation | 4/28 | 85 ± 7 |
| Group . | Events/patients, no. . | 5-y EFS ± SE, % . | P . |
|---|---|---|---|
| Investigational window, | |||
| Dexamethasone (mg/m2/d) | |||
| 6 | 14/88 | 85 ± 4 | .73 |
| 18 | 18/89 | 80 ± 5 | |
| 150 | 17/86 | 79 ± 5 | |
| Prednisone (mg/m2/d) | |||
| 40 | 13/85 | 87 ± 4 | |
| Asparaginase preparation | |||
| E coli | 15/92 | 84 ± 4 | .29 |
| PEG | 24/106 | 78 ± 4 | |
| 6-MP dosing | |||
| Standard dose (PO) | 26/163 | 84 ± 3 | .90 |
| High dose (IV) | 26/159 | 85 ± 3 | |
| Doxorubicin infusion rate (HR only) | |||
| Bolus | 20/102 | 80 ± 4 | .23 |
| Continuous infusion for 48 h | 14/102 | 86 ± 4 | |
| CNS radiation fractionation | |||
| HR only | |||
| Conventional | 12/96 | 87 ± 3 | .05 |
| Hyperfractionation | 23/97 | 76 ± 4 | |
| SR only | |||
| Conventional | 5/31 | 90 ± 5 | .84 |
| Hyperfractionation | 4/28 | 85 ± 7 |
See Table 1 and Table 2 for abbreviations.